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M A N U S C R I P T A C C E P T E D INTRODUCTION
Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality 1, 2 . The objectives of screening for PE are firstly, to reduce the prevalence of the disease through pharmacological intervention in the high-risk group identified in the first-trimester of pregnancy 3, 4 and secondly, to minimize adverse perinatal events for those that develop PE by determining the appropriate time and place for delivery 5 . The second objective can be potentially achieved through screening in the second and / or the third-trimester of pregnancy.
The traditional approach to screening for PE is to use a risk-scoring system based on maternal demographic characteristics and medical history (maternal factors) 6, 7 . However, the performance of such approach, which essentially treats each risk factor as a separate screening test with additive detection rate (DR) and screen positive rate, is poor [8] [9] [10] . Similarly, studies have investigated the potential value of biomarkers in predicting PE by examining the proportion of affected and unaffected pregnancies exceeding a cut-off in the measurement of such biomarkers [11] [12] [13] [14] [15] [16] [17] . An alternative approach to screening, which allows estimation of individual patient-specific risks of PE is to use Bayes theorem to combine the a priori risk from maternal factors, derived by a multivariable logistic model, with the results of various combinations of biophysical and biochemical markers [8] [9] [10] . However, the measured levels of biomarkers depend on variables from maternal characteristics and medical history and for their effective use in risk assessment and screening these covariates need to be taken into account; this can be achieved by standardising biomarker levels into multiples of the normal median (MoM) values [18] [19] [20] [21] .
We have previously reported that first-trimester screening by a combination of maternal factors with MoM values of mean arterial pressure (MAP), uterine artery pulsatility index (UTPI) and serum placental growth factor (PLGF) could predict 65% of preterm-PE and 33% of term-PE, at 5% false positive rate (FPR) 9 . Screening at 19-24 weeks by maternal factors, MAP, UTPI and PLGF improved the DR of preterm-PE to about 75%, but the DR of term-PE remained at 33% 10 . There is some evidence that the prediction of both preterm-PE and term-PE is improved by screening in the early third-trimester than at 19-24 weeks. We have previously reported on the development of a model of screening for PE by a combination of MAP, UTPI, PLGF and serum soluble fms-like tyrosine kinase-1 (SFLT) at 32 weeks, but the performance of screening was assessed by simulating from the fitted model and such approach is generally optimistically biased because it ignores errors of estimation and departures from the assumed model 22 . . In the first phase of the study, only UTPI was measured, then measurement of MAP was added and in the final phase serum concentration of PLGF was measured and then SFLT was added. The inclusion criteria, which were the same throughout the study, were singleton pregnancy delivering a non-malformed live birth or stillbirth at >24 weeks' gestation. We excluded pregnancies with aneuploidies and major fetal abnormalities and those ending in termination, miscarriage or fetal death at <24 weeks.
M A N U S C R I P T A C C E P T E D
The left and right UTPI were measured by transabdominal color Doppler ultrasound and the mean PI was calculated 23 . Measurements of MAP were obtained by validated automated devices and a standardized protocol 24 . Measurement of serum concentration of PLGF and SFLT were by an automated biochemical analyzer within 10 minutes of blood sampling (Cobas e411 system, Roche Diagnostics, Penzberg, Germany). The inter-assay coefficients of variation for low and high concentrations were 5.4% and 3.0% for PlGF, and 3.0% and 3.2% for SFLT, respectively. Gestational age was determined from measurement of fetal crown-rump length (CRL) at 11-13 weeks or the fetal head circumference at 19-24 weeks 25, 26 . The women gave written informed consent to participate in the study, which was approved by the NHS Research Ethics Committee.
Outcome measures
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The obstetric records of all women with pre-existing or pregnancy associated hypertension were examined to determine if the condition was PE or pregnancy induced hypertension (PIH), as defined by the International Society for the Study of Hypertension in Pregnancy 27 . Outcome measures were PE delivering at <37 weeks' gestation (preterm-PE) and at >37 weeks (term-PE). The unaffected group contained all pregnancies without PE or PIH.
Statistical analyses
Performance of screening was assessed firstly, by examining the empirical results in 7,927 pregnancies with complete data on MAP, UTPI, PLGF and SFLT, secondly, by examining the empirical results using all available data for each biomarker and thirdly, by modeling, whereby values on biomarkers were simulated for our 123,406 singleton pregnancies with available data on maternal factors 10 . In selecting the second option, we wanted to have the maximum possible data for developing the models and examining performance of the various biomarkers; for example, in examining UTPI we could use data from 30,935 pregnancies, rather than just 7,927. However, the distribution of maternal factors was not identical in each subset used for assessment of each biomarker or their combinations; consequently, there were differences between the datasets in the maternal factor related performance of screening and it was therefore difficult to compare meaningfully the additional contribution to performance between biomarkers and their combinations over and above that of maternal factors alone. To overcome this problem we obtained modeled estimates of performance by sampling biomarker multiple of the normal median (MoM) values from the fitted multivariate log Gaussian distribution in the large dataset of 123,406 pregnancies.
Competing risks model M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
This model assumes that if the pregnancy was to continue indefinitely all women would develop PE and whether they do so or not before a specified gestational age depends on competition between delivery for PE or for other reasons 28 . The effect of each maternal factor is to modify the mean of the distribution of gestational age at delivery with PE so that in pregnancies at low-risk for PE the gestational age distribution is shifted to the right with the implication that in most pregnancies delivery will actually occur for other reasons before development of PE. In high-risk pregnancies, the distribution is shifted to the left and the smaller the mean gestational age the higher is the risk for PE. The distribution of biomarkers is specified conditionally on the gestational age at delivery with PE. For any women with specific maternal factors and biomarker MoM, the posterior distribution of the time to delivery with PE is obtained from the application of Bayes theorem.
Gestational age at delivery with PE was defined by two components: firstly, the prior distribution based on maternal factors 8 and secondly, the conditional distribution of MoM biomarker values given the gestational age with PE and maternal factors. Values of MAP, UTPI, PLGF and SFLT were expressed as MoMs adjusting for those characteristics found to provide a substantive contribution to their values, including the maternal factors in the prior model [18] [19] [20] [21] . In the PE group, the mean log 10 MoM was assumed to depend linearly with gesational age at delivery and this linear relationship was assumed to continue until the mean log 10 MoM of zero, beyond which the mean was taken as zero; this assumption was confirmed by the empirical results shown in Figure 1 . Multivariable Gaussian distributions were fitted to the log 10 MoM values of the biomarkers and a common covariance matrix was assumed for these distributions. Analysis of residuals was used to check the adequacy of the model and assess the effects of maternal factors on log 10 transformed MoM values in pregnancies with PE.
Empirical performance of screening
Ten-fold cross validation was used to assess the empirical performance of screening for PE by maternal factors and the combination of maternal factors with biomarkers. The data were divided into 10 equal subgroups, the model was then fitted 10 times to different combinations of nine of the 10 subgroups and used to predict risk of PE in the remaining tenth of the data. In each case, the maternal factor model, the regression models, and the covariance matrix were fitted to the training data set comprising nine tenths on the data and used to produce risks for the hold out sample comprising the remaining tenth of the data. The positive and negative likelihood ratios
Model-based estimates of screening performance
To provide model-based estimates of screening performance, the following procedure was adopted. First, we obtained the dataset of 123,406 singleton pregnancies, including 2,748 (2.2%) with PE, that was previously used to develop a model for PE based on maternal demographic characteristics and medical history 8 . Second, for each case of PE (n=2,748) and pregnancies unaffected by PE or PIH (n=117,710), the biophysical and biochemical MoM values were simulated from the fitted multivariate Gaussian distribution for log transformed MoM values. Third, risks were obtained using the competing risk model from the simulated MoM values and the pregnancy characteristics. These three steps were applied to the pregnancies within the unaffected group with no restriction on the time of delivery. Fourth, for a given FPR, risks from the unaffected group were used to define a risk cut-off. The proportion of PE risks was then used to obtain an estimate of the
The area under the receiver operating characteristic curve (AUROC) was also calculated. The simulations were repeated 100 times to reduce variability due to the simulation process and provide suitably precise model-based estimates of performance.
Performance of biomarkers without adjustment for maternal factors.
The 90 th and 95 th percentiles for UTPI, MAP and SFLT and the 10 th and 5 th percentiles for PLGF were derived from the measurements of these biomarkers in unaffected pregnancies without conversion to MoM values. The performance of screening for PE was estimated using these percentile cut-offs.
The statistical software package R was used for data analyses 29 . The survival package 30 was used for fitting the maternal factors model and the package pROC 31 was used for the receiver operating characteristic (ROC) curve analysis.
RESULTS

Characteristics of the study population
The characteristics of the pregnancies with data on MAP, UTPI, PLGF and SFLT are given in Table S1 , those of the 7,927 pregnancies with complete data on UTPI, MAP, PLGF and SFLT are given in Table S2 and those of the total population of 123,406 pregnancies with maternal factors are given in Table S3 .
Distribution of biomarkers
The distributions of log 10 MoM values of the biomarkers in unaffected pregnancies and in those that developed PE are shown in Tables S4 and S5. In the unaffected group, the median MoM value is 1.0 and on the log scale the distribution of MoM values is very well approximated by a Gaussian distribution with mean zero. The MoM values in the PE group and the fitted regression relationships with gestational age at delivery are shown in Figure 1 . All markers showed more separation at earlier than later gestations and this is reflected in their superior performance at detection of preterm-PE than term-PE.
The distribution of measurements of biomarkers without adjustment for maternal factors is shown in Figure S1 . The 90 th and 95 th percentiles for MAP were 96.9 and 100.0 mmHg, and the respective values for UTPI were 1.03 and 1.17 and for SFLT were 3,187 and 3,887 pg/mL. The 10 th and 5 th percentiles for PLGF were 206.3 and 150.6 pg/mL, respectively. (Table 1) is compatible with the performance in the 7,927 pregnancies with complete data (Table S6 ), but in the latter the confidence intervals are wider because of fewer data. The empirical DRs are also compatible with the model-based rates, but the latter are optimistically biased (Table 1) . Table 2 provides the positive and negative LRs for preterm-PE and term-PE. The AUROC curves for prediction of PE and model-based results are shown in Table 3 . Figure 3 shows the empirical performance of screening for PE by combination of maternal factors with all available data on biomarkers; the empirical results are compatible with the model-based results.
Performance of screening for preeclampsia
The performance of screening for preterm-PE and term-PE by individual biomarkers using percentile cut-offs from unadjusted measurements, compared to our approach of combining the prior risk from maternal factors with biomarker MoM values is shown in Table 4 ; in general, the DR from combined screening was higher, particularly for term-PE.
COMMENT
Principal findings of this study
In pregnancies that develop PE, the early third-trimester values of UTPI, MAP and SFLT are increased and PLGF is decreased. For all biomarkers the deviation from normal is inversely related to the gestational age at which delivery becomes necessary for maternal and or fetal indications and therefore, the performance of screening is better for preterm-PE than term-PE.
The performance of screening achieved by maternal factors is improved by the addition of MAP, UTPI, PLGF or SFLT. Although the study provides some evidence on the potential value of various combinations of biomarkers, it was not powered to demonstrate significant improvement in performance with the addition of one or more biomarkers to that achieved by a combination of maternal factors with any one of the biomarkers.
Screening for PE by a combination of maternal factors, MAP, UTPI, PLGF and SFLT at 30-34 weeks' gestation could predict, at 5% FPR, 98% of preterm-PE and 49% of term-PE. Consequently, the performance of screening at 30-34 weeks is superior to that achieved by screening at 11-13 or 19-24 weeks with respective DRs of about 65% and 75% for preterm-PE and 33% for term-PE 9, 10 . In screening by all biomarkers, a screen positive result at 5% FPR, is associated with a 20-fold increase in odds ratio for preterm-PE and 11-fold increase for term-PE; a screen negative result is associated with a 42-fold decrease in odds ratio for preterm-PE and 2-fold decrease for term-PE.
The traditional approach to screening for PE is to use individual factors from maternal characteristics and obstetric history or the results of individual biomarker percentile cut-offs to define the screen positive group. This is analogous to screening for Down syndrome by individual cut-offs in maternal age, first-trimester fetal nuchal translucency thickness, serum PAPP-A or free ß-hCG. Our proposed approach to screening for PE, which utilizes Bayes theorem to combine maternal factors with multiple biomarkers, has a performance which is superior to that achieved with screening by maternal factors alone or individual biomarkers alone. We found that at 5% FPR, the DR of preterm-PE in screening by our approach using all four biomarkers was 98% (95% CI 88-100%), compared to 81% in screening with SFLT, which was the best of the individual biomarkers. This concept is now well accepted in screening for Down syndrome where a combined risk cut-off, rather than individual biomarker cut-offs, is used to guide pregnancy management and there is no reason to believe that the same philosophy could not be adopted in screening for PE and other pregnancy complications. The software for such estimation of combined risk for PE is freely available (website Am JOG).
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Strengths and limitations
The strengths of this early third-trimester screening study for PE are first, examination of a large population of pregnant women attending for routine care in a gestational age range which is widely used for assessment of fetal growth and wellbeing, second, recording of data on maternal characteristics and medical history to define the prior risk, third, use of a specific methodology and appropriately trained doctors to measure MAP and UTPI, fourth, use of automated machines to provide accurate measurement within 40 minutes of sampling of maternal serum concentration of PLGF and SFLT, fifth, expression of the values of the biomarkers as MoMs after adjustment for factors that affect the measurements, and sixth, use of Bayes theorem to combine the prior risk from maternal factors with biomarkers to estimate patient-specific risks and the performance of screening for PE delivering at different stages of pregnancy.
A limitation of the study is that some of the findings rely on modeling which introduces optimistic bias. We have used 10-fold cross validation on the empirical data which reduces such bias and demonstrated that the performance was compatible with that derived from modeling.
Comparison with previous studies
Previous studies examining biomarkers in the late second or early third trimesters of pregnancy have essentially focused on the investigation of women presenting to specialist clinics with signs of hypertensive disorders with the aim of identifying the subgroup that will develop severe disease [11] [12] [13] [14] [15] [16] [17] 32 . Our study examined the application of biomarkers in routine screening for subsequent development of PE as part of a strategy for a new approach to prenatal care 33 .
Clinical implications of the study
In the traditional approach to prenatal care, screening and diagnosis of PE is based on the demonstration of elevated blood pressure and proteinuria during a routine clinical visit in the late second-or third-trimester of pregnancy. In a proposed new pyramid of pregnancy care 33 , the timing and content of clinical visits should be defined by the patient-specific risk of developing PE; the objective would be to minimize adverse perinatal events for those that develop PE by determining the appropriate time and place for delivery.
Stratification of risk for PE can be achieved by a combination of maternal factors and biomarkers, but there is an inherent contradiction in selecting the best time for such assessment. The incidence of PE increases with gestational age; in our study population of 123,406 singleton pregnancies, there were 2,748 cases of PE and the gestational age at delivery of the PE group was <32 weeks in 9% of cases, 32 +0 -36 +6 weeks in 20% and >37 weeks in 71%. In contrast, the incidence of adverse fetal and maternal short-term and long-term consequences of PE is inversely related to the gestational age at onset of the disease [34] [35] [36] [37] [38] [39] . Similarly, the performance of screening for PE at any gestational age is inversely related to the gestational age at delivery with PE. Screening at around 22 weeks' gestation could identify, at 5% FPR, all cases of early-PE requiring delivery at <32 weeks, but only 65% of PE at 32 +0 -36 +6 weeks and 33% of PE at >37 weeks 10 . The present study has shown that screening at around 32 weeks' gestation could identify, at 5% FPR,
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98% of cases of PE requiring delivery at 32 +0 -36 +6 weeks, but only 49% of PE at >37 weeks. In another screening study at around 36 weeks' gestation, we found that about 85% of cases of PE at >37 weeks could be identified at 10% FPR 40 .
Future studies will firstly, define contingent strategies for appropriate selection of patients that would benefit from assessment at 22, 32 and / or 36 weeks' gestation, secondly, develop management protocols for the high-risk pregnancies identified at such visits and thirdly, examine whether the implementation of such protocols could improve perinatal outcome. 
20 Table 3 . Areas under the receiver operating characteristic curve of empirical results and model-based results in screening for preeclampsia by maternal factors and combination of maternal factors and biomarkers. PE = preeclampsia; CI = confidence interval; UTPI = uterine artery pulsatility index; MAP = mean arterial pressure; PLGF = placental growth factor; SFLT = soluble fms-like tyrosine kinase-1. In the regression models, gestational age was centred at 24 weeks so the intercept represents the mean at 24 weeks.
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M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 6   Table S5 . Standard deviations and correlations, with 95% confidence limits, for log 10 multiples of the median biomarker values.
Pooled refers to estimates obtained from pooling data for the preeclampsia and no preeclampsia groups. MAP = mean arterial pressure; UTPI = uterine artery pulsatility index; PLGF = placental growth factor; SFLT= soluble fms-like tyrosine kinase-1. 
Unaffected
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A C C E P T E D ACCEPTED MANUSCRIPT 7   Table S6 . Empirical performance of screening for preeclampsia in the subgroup of 7,748 pregnancies with complete data on all biomarkers. PE = preeclampsia; CI = confidence interval; MAP = mean arterial pressure; UTPI = uterine artery pulsatility index; PLGF = placental growth factor; SFLT = soluble fms-like tyrosine kinase-1. 
